Loading...

3SBio Inc.

1530.HKHKSE
HealthcareBiotechnology
HK$19.44
HK$-0.20(-1.02%)

3SBio Inc. 1530.HK Peers

See (1530.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1530.HKHK$19.44-1.02%45.8B20.90HK$0.93+1.29%
1801.HKHK$72.30-2.63%119.3B-1032.86-HK$0.07N/A
2269.HKHK$24.90-1.19%101.3B29.29HK$0.85N/A
1177.HKHK$4.53-1.95%81B41.18HK$0.11+1.32%
9926.HKHK$81.95+0.99%73.5B-126.08-HK$0.65N/A
3759.HKHK$15.76-2.48%43.5B13.70HK$1.15+1.64%
6821.HKHK$70.70-3.68%33.7B23.03HK$3.07+2.56%
1877.HKHK$21.40-6.14%32.2B-13.81-HK$1.55N/A
9688.HKHK$28.55+5.35%31.4B-12.98-HK$2.20N/A
2096.HKHK$12.26-1.92%30.5B38.31HK$0.32+1.43%
Showing 1 to 10 of 56 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1530.HK vs 1801.HK Comparison

1530.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1530.HK stands at 45.8B. In comparison, 1801.HK has a market cap of 119.3B. Regarding current trading prices, 1530.HK is priced at HK$19.44, while 1801.HK trades at HK$72.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1530.HK currently has a P/E ratio of 20.90, whereas 1801.HK's P/E ratio is -1032.86. In terms of profitability, 1530.HK's ROE is +0.14%, compared to 1801.HK's ROE of -0.01%. Regarding short-term risk, 1530.HK is less volatile compared to 1801.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1530.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions